Literature DB >> 3013397

HTLV-I seroprevalence in patients with malignancy.

N Asou, T Kumagai, S Uekihara, M Ishii, M Sato, K Sakai, H Nishimura, K Yamaguchi, K Takatsuki.   

Abstract

Since many malignancies often occur in patients with smoldering type adult T-cell leukemia (ATL) (5 of 18 cases in this report), the relationship between HTLV-I (human T-cell leukemia virus type I) infection, which is closely associated with ATL, with other malignancies in an HTLV-I endemic area was examined. Among the 394 patients with malignancies and who had not had blood cell transfusions, 61 (15.5%) tested positive for HTLV-I antibody. The prevalence was significantly higher in males older than age 40 years and females of all ages compared to age- and sex-matched healthy individuals. The overall seroprevalence (26.1%) in 291 patients with malignancies and who had had blood cell transfusions was higher than that of those who had not had blood transfusions. There was no significant correlation between the site of malignancy and antibody prevalence. These results suggest the possibility that development of malignancy may contribute to expression of latent HTLV-I infection and that HTLV-I infection may contribute to the risk of other malignancies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013397     DOI: 10.1002/1097-0142(19860815)58:4<903::aid-cncr2820580417>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Follow-up of asymptomatic HTLV-I carriers among blood donors in Kyushu, Japan.

Authors:  S Tokudome; Y Maeda; K Fukada; D Teshima; T Asakura; E Sueoka; Y Motomura; Y Kusumoto; Y Imamura; T Kiyokawa
Journal:  Cancer Causes Control       Date:  1991-03       Impact factor: 2.506

Review 2.  Malignant lymphomas in Japan: epidemiological analysis of adult T-cell leukemia/lymphoma (ATL).

Authors:  K Tajima
Journal:  Cancer Metastasis Rev       Date:  1988-11       Impact factor: 9.264

3.  Incidence of anti-HTLV-1 antibody in liver disease.

Authors:  H Nakano; M Sata; K Hino; T Aritaka; N Maruyama; T Hino; H Abe; K Tanikawa; M Mizokami
Journal:  Gastroenterol Jpn       Date:  1992-02

Review 4.  Adult T-cell leukemia-lymphoma.

Authors:  S M Neely
Journal:  West J Med       Date:  1989-05

Review 5.  Development of peripheral T-cell lymphoma not otherwise specified in an HTLV-1 carrier.

Authors:  Tomohiro Ishigaki; Masamichi Isobe; Seiichiro Kobayashi; Koichiro Yuji; Nobuhiro Ohno; Nobukazu Watanabe; Arinobu Tojo; Kaoru Uchimaru
Journal:  Int J Hematol       Date:  2013-04-09       Impact factor: 2.490

6.  Concomitant presence of bladder cancer and neurogenic bladder in a patient with HTLV-1 carrier: a case report.

Authors:  H Yagi; M Igawa; H Shiina; K Shigeno
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.266

7.  Performance certification of gelatin particle agglutination assay for anti-HTLV-1 antibody: inconclusive positive results.

Authors:  Y Maeda; J Imai; H Kiyokawa; M Kanamura; S Hino
Journal:  Jpn J Cancer Res       Date:  1989-10

8.  Mortality among inhabitants of an HTLV-I endemic area in Japan.

Authors:  K Iwata; S Ito; H Saito; M Ito; M Nagatomo; T Yamasaki; S Yoshida; H Suto; K Tajima
Journal:  Jpn J Cancer Res       Date:  1994-03

9.  Increased prevalence of HTLV-I infection in patients with hepatocellular carcinoma associated with hepatitis C virus.

Authors:  A Okayama; T Maruyama; N Tachibana; K Hayashi; T Kitamura; N Mueller; H Tsubouchi
Journal:  Jpn J Cancer Res       Date:  1995-01

10.  Human T-cell Leukemia Virus Type I Associated with an Increased Risk of Primary Malignant Neoplasm.

Authors:  Aya Nakaya; Shinya Fujita; Atsushi Satake; Takahisa Nakanishi; Yoshiko Azuma; Yukie Tsubokura; Akiko Konishi; Masaaki Hotta; Hideaki Yoshimura; Kazuyoshi Ishii; Tomoki Ito; Shosaku Nomura
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-04-20       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.